Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study

Shinnosuke Takemoto; Minoru Fukuda; Hiroyuki Yamaguchi; Takaya Ikeda; Kazumasa Akagi; Hiromi Tomono; Yasuhiro Umeyama; Yosuke Dotsu; Hirokazu Taniguchi; Hiroshi Gyotoku; Hiroaki Senju; Takeshi Kitazaki; Katsumi Nakatomi; Seiji Nagashima; Masaaki Fukuda; Akitoshi Kinoshita; Hiroshi Soda; Hiroshi Mukae

doi:10.1111/1759-7714.13279

Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study

Shinnosuke Takemoto, Minoru Fukuda, Hiroyuki Yamaguchi, Takaya Ikeda, Kazumasa Akagi, Hiromi Tomono, Yasuhiro Umeyama, Yosuke Dotsu, Hirokazu Taniguchi, Hiroshi Gyotoku, Hiroaki Senju, Takeshi Kitazaki, Katsumi Nakatomi, Seiji Nagashima, Masaaki Fukuda, Akitoshi Kinoshita, Hiroshi Soda, Hiroshi Mukae

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Introduction: Anti-vascular endothelial growth factor therapy has been shown to be effective in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects. Methods: We therefore decided to conduct a phase II study of ramucirumab plus docetaxel for NSCLC patients with MPE. The MPE control rate at eight weeks after the start of treatment will be the primary endpoint, and the objective response rate, progression-free survival, one-year survival rate, overall survival, and toxicity profile will be secondary endpoints. Discussion: A previous study indicated that administering chemotherapy in combination with bevacizumab was effective at controlling pleural effusion in patients with NSCLC with carcinomatous pleurisy. It is expected that ramucirumab will have a similar effect to the same group.

Original language	English
Pages (from-to)	389-393
Number of pages	5
Journal	Thoracic Cancer
Volume	11
Issue number	2
DOIs	https://doi.org/10.1111/1759-7714.13279
State	Published - 1 Feb 2020
Externally published	Yes

Keywords

NSCLC
docetaxel
pleural effusion
ramucirumab

Access to Document

10.1111/1759-7714.13279

Cite this

Takemoto, S., Fukuda, M., Yamaguchi, H., Ikeda, T., Akagi, K., Tomono, H., Umeyama, Y., Dotsu, Y., Taniguchi, H., Gyotoku, H., Senju, H., Kitazaki, T., Nakatomi, K., Nagashima, S., Fukuda, M., Kinoshita, A., Soda, H., & Mukae, H. (2020). Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study. Thoracic Cancer, 11(2), 389-393. https://doi.org/10.1111/1759-7714.13279

@article{0fbace880898491b90e8f697544889e1,

title = "Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study",

abstract = "Introduction: Anti-vascular endothelial growth factor therapy has been shown to be effective in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects. Methods: We therefore decided to conduct a phase II study of ramucirumab plus docetaxel for NSCLC patients with MPE. The MPE control rate at eight weeks after the start of treatment will be the primary endpoint, and the objective response rate, progression-free survival, one-year survival rate, overall survival, and toxicity profile will be secondary endpoints. Discussion: A previous study indicated that administering chemotherapy in combination with bevacizumab was effective at controlling pleural effusion in patients with NSCLC with carcinomatous pleurisy. It is expected that ramucirumab will have a similar effect to the same group.",

keywords = "NSCLC, docetaxel, pleural effusion, ramucirumab",

author = "Shinnosuke Takemoto and Minoru Fukuda and Hiroyuki Yamaguchi and Takaya Ikeda and Kazumasa Akagi and Hiromi Tomono and Yasuhiro Umeyama and Yosuke Dotsu and Hirokazu Taniguchi and Hiroshi Gyotoku and Hiroaki Senju and Takeshi Kitazaki and Katsumi Nakatomi and Seiji Nagashima and Masaaki Fukuda and Akitoshi Kinoshita and Hiroshi Soda and Hiroshi Mukae",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley \& Sons Australia, Ltd",

year = "2020",

month = feb,

day = "1",

doi = "10.1111/1759-7714.13279",

language = "English",

volume = "11",

pages = "389--393",

journal = "Thoracic Cancer",

issn = "1759-7706",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

Takemoto, S, Fukuda, M, Yamaguchi, H, Ikeda, T, Akagi, K, Tomono, H, Umeyama, Y, Dotsu, Y, Taniguchi, H, Gyotoku, H, Senju, H, Kitazaki, T, Nakatomi, K, Nagashima, S, Fukuda, M, Kinoshita, A, Soda, H & Mukae, H 2020, 'Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study', Thoracic Cancer, vol. 11, no. 2, pp. 389-393. https://doi.org/10.1111/1759-7714.13279

TY - JOUR

T1 - Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion

T2 - Protocol of PLEURAM study

AU - Takemoto, Shinnosuke

AU - Fukuda, Minoru

AU - Yamaguchi, Hiroyuki

AU - Ikeda, Takaya

AU - Akagi, Kazumasa

AU - Tomono, Hiromi

AU - Umeyama, Yasuhiro

AU - Dotsu, Yosuke

AU - Taniguchi, Hirokazu

AU - Gyotoku, Hiroshi

AU - Senju, Hiroaki

AU - Kitazaki, Takeshi

AU - Nakatomi, Katsumi

AU - Nagashima, Seiji

AU - Fukuda, Masaaki

AU - Kinoshita, Akitoshi

AU - Soda, Hiroshi

AU - Mukae, Hiroshi

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Introduction: Anti-vascular endothelial growth factor therapy has been shown to be effective in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects. Methods: We therefore decided to conduct a phase II study of ramucirumab plus docetaxel for NSCLC patients with MPE. The MPE control rate at eight weeks after the start of treatment will be the primary endpoint, and the objective response rate, progression-free survival, one-year survival rate, overall survival, and toxicity profile will be secondary endpoints. Discussion: A previous study indicated that administering chemotherapy in combination with bevacizumab was effective at controlling pleural effusion in patients with NSCLC with carcinomatous pleurisy. It is expected that ramucirumab will have a similar effect to the same group.

AB - Introduction: Anti-vascular endothelial growth factor therapy has been shown to be effective in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion (MPE); however, there are no data to suggest that ramucirumab has the same effects. Methods: We therefore decided to conduct a phase II study of ramucirumab plus docetaxel for NSCLC patients with MPE. The MPE control rate at eight weeks after the start of treatment will be the primary endpoint, and the objective response rate, progression-free survival, one-year survival rate, overall survival, and toxicity profile will be secondary endpoints. Discussion: A previous study indicated that administering chemotherapy in combination with bevacizumab was effective at controlling pleural effusion in patients with NSCLC with carcinomatous pleurisy. It is expected that ramucirumab will have a similar effect to the same group.

KW - NSCLC

KW - docetaxel

KW - pleural effusion

KW - ramucirumab

UR - https://www.scopus.com/pages/publications/85076927203

U2 - 10.1111/1759-7714.13279

DO - 10.1111/1759-7714.13279

M3 - Article

C2 - 31851428

AN - SCOPUS:85076927203

SN - 1759-7706

VL - 11

SP - 389

EP - 393

JO - Thoracic Cancer

JF - Thoracic Cancer

IS - 2

ER -

Phase II study of ramucirumab and docetaxel for previously treated non-small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study

Abstract

Keywords

Access to Document

Fingerprint

Cite this